The 16th Biennial Rivkin Ovarian Cancer Research Symposium will take place on October 16-18, 2026 at the Sheraton Philadelphia Downtown in Philadelphia, PA.
ocrahope.org/research/riv...
GD T cells expressing the Cγ1 constant region exhibit a more differentiated cytotoxic effector phenotype, independently of interchain disulfide bond configuration. TRGC1 shows preferential pairing with TRGV8/TRGV9 variable segments, suggesting increased specificity to tumor antigens and pathogens.
Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
ir.anixa.com/press-releas...
Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
ir.anixa.com/press-releas...
Beautiful study by Sungjune Kim and Imene Hamaidi at Mayo on how SIRT2-driven LCK acetylation elevates the threshold of TCR activation, which can be targeted with inhibitors and genetic approaches in real world tumor-reactive TILs. True immunology:
rdcu.be/e1iSA
Great story from Carlos Ontiveros and Tyler Curiel on the role opf PD-L2 in anti-tumor immunity in old subjects with melanoma.
PD-L1 and PD-1 blockade are often equated but biologically it is not the same and they may have different clinical applications.
rdcu.be/eQWiw
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization:
ir.anixa.com/press-releas...
The promise of TIL therapy for glioblastoma.
Inspiring perspective from Mustafa Kharaw's team on their ongoing work to make immunotherapy effective against one of the most devastating human cancers:
www.sciencedirect.com/science/arti...
Anixa Biosciences, Inc. (ANIX), which is testing CER T cells redirected against FSHR with FSH in patients with relapsed, chemoresisatnt ovarian cancer, will participate in the upcoming Water Tower Research Fireside Chat Series (November 11, 2025, at 11:00am PT)
us06web.zoom.us/webinar/regi...
Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathy | Science Translational Medicine www.science.org/doi/10.1126/...
Medicine Nobel for researchers who characterized the immunobiology of regulatory T cells (previously "suppressor T cells"):
www.science.org/content/arti...
Thanks indeed to all program officers and grant manager specialists at the NIH. I admire their resilience and commitment to keeping the NIH as the best science funding agency in the world even when tehm are under assault by the administration. It is clear who is on the side of Science and who is not
working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era url: academic.oup.com/jnci/article...
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology:
ir.anixa.com/press-releas...
Immune memory shapes ovarian cancer recurrence:
Comment on the article of Ghisoni and Dangaj in Cancer Cell www.cell.com/cancer-cell/...
Dr. Robert Wenham, principal investigator for Anixa's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will be presenting at the 13th Annual Ovarcoming Cancer Conference, being held September 18 – 19, 2025, at the Briar Club in Houston, Texas.
ir.anixa.com/press-releas...
I am disappointed and alarmed that millions of Americans listen to these comments and do not see anything fundamentally wrong and indicative of a psychopathy.
This is important, among other reasons, because ICIs failed in relapsed ovarian cancers, questioning whether relapsed tumors lost immunogenicity.
Although analyses of neoantigens and TCR frequencies are ongoing, it is clear that tumors re-establish the immuno-environment (e.g., TIL patterns).
This new study from Dangaj& Ghisoni in Cancer Cell analyzed 131 matching primary/relapsed ovarian cancers, to show that the immune landscape of the original tumor is re-established in the recurrent lesion, which depends on HRD status and pre-existing TIL:myeloid niches. www.cell.com/cancer-cell/...
Federal government freezes $108 million in NIH funding to Duke. Apparently for racial discrimination...against white Anglos in the Deep South...this sounds like a Tarantino movie... www.dukechronicle.com/article/2025...
In this new study, Aaron Ring and colleagues demonstrate the importance of antibody responses on the effectiveness of patients with cancer treated with ICI. As for treatment naive tumors, these are autoandibodies thsat in most cases do not cause autoimmunity:
rdcu.be/exGyT
There is at least some attention from the press to the devastation of the scientific enterprise that is going on...
Trump Seeks to Cut Basic Scientific Research by Roughly One-Third, Report Shows www.nytimes.com/2025/07/10/s...
Improving lung cancer tumor infiltrating lymphocytes (TILs) manufacturing - Cytotherapy www.isct-cytotherapy.org/article/S146...
In immunology, for instance, experiments can only be done in vivo to capture the complex interactions of multiple cell types, cytokines and chemokines. No computer will predict immune subsets and mediators that we do not fully understand yet.
NIH announces end to funding for animal-only studies. This is potentially catastrophic. www.drugdiscoverytrends.com/nih-announce...
Zelig Eshhar, leading cancer researcher and immunologist, and the father of CAR T cells, dies at 84:
www.timesofisrael.com/zelig-eshhar...
Great article from Tao wang in Nature Cancer:
The abundance of tumor antigen-targeting antibodies is predictive of ICI response. Plus a new computational method to predict binding between antibodies and antigens that can be scaled to high-throughput sequencing data
www.nature.com/articles/s43...
Building Better Immunotherapy: Using a method spearheaded by led by José Ramón Conejo-Garcia, MD, PhD, and Scott Antonia, MD, PhD (pictured here), immune cells are being engineered to find and attack cancer tumors.
🔗: medschool.duke.edu/stories/buil...
#AcademicSky #MedSky #Immunobiology
They did not need to delay the progress of biomedical research for many years, ruining the life of thousands of valuable people in the process, to find that people mostly work in government because they believe in the mission of the agency. Very efficiently for what they earn
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial. No dose-limiting toxicities were observed in the third cohort.
The trial is enrolling women with recurrent ovarian cancer who have progressed after two prior therapies.
ir.anixa.com/press-releas...
